Research

Jump to: Review

12 pages, 1114 KiB

Open AccessArticle

Safety and Potential Role of Lactobacillus rhamnosus GG Administration as Monotherapy in Ulcerative Colitis Patients with Mild–Moderate Clinical Activity

by Cristiano Pagnini, Maria Carla Di Paolo, Riccardo Urgesi, Lorella Pallotta, Gianfranco Fanello, Maria Giovanna Graziani and Gianfranco Delle Fave

Microorganisms 2023, 11(6), 1381; https://doi.org/10.3390/microorganisms11061381 - 24 May 2023

Cited by 1 | Viewed by 1709

Abstract

Probiotics are microorganisms that confer benefits to the host, and, for this reason, they have been proposed in several pathologic states. Specifically, probiotic bacteria have been investigated as a therapeutic option in ulcerative colitis (UC) patients, but clinical results are dishomogeneous. In particular, [...] Read more.

Probiotics are microorganisms that confer benefits to the host, and, for this reason, they have been proposed in several pathologic states. Specifically, probiotic bacteria have been investigated as a therapeutic option in ulcerative colitis (UC) patients, but clinical results are dishomogeneous. In particular, many probiotic species with different therapeutic schemes have been proposed, but no study has investigated probiotics in monotherapy in adequate trials for the induction of remission. Lactobacillus rhamnosus GG (LGG) is the more intensively studied probiotic and it has ideal characteristics for utilization in UC patients. The aim of the present study is to investigate the clinical efficacy and safety of LGG administration in an open trial, delivered in monotherapy at two different doses, in UC patients with mild–moderate disease. The UC patients with mild–moderate disease activity (Partial Mayo score ≥ 2) despite treatment with oral mesalamine were included. The patients stopped oral mesalamine and were followed up for one month, then were randomized to receive LGG supplement at dose of 1.2 or 2.4 × 10¹⁰ CFU/day for one month. At the end of the study, the clinical activity was evaluated and compared to that at the study entrance (efficacy). Adverse events were recorded (safety). The primary end-point was clinical improvement (reduction in the Partial Mayo score) and no serious adverse events, while the secondary end-points were the evaluation of different efficacies and safeties between the two doses of LGG. The patients with disease flares dropped out of the study and went back to standard therapy. The efficacy data were analyzed in an intention-to-treat (ITT) and per-protocol (PP) analysis. Out of the 76 patients included in the study, 75 started the probiotic therapy (n = 38 and 37 per group). In the ITT analysis, 32/76 (42%) responded to treatment, 21/76 (28%) remained stable, and 23/76 (30%) had a worsening of their clinical condition; 55 (72%) completed the treatment and were analyzed in a PP analysis: 32/55 (58%) had a clinical response, 21 (38%) remained stable, and 2 (4%) had a light worsening of their clinical condition (p < 0.0001). Overall, 37% of the patients had a disease remission. No severe adverse event was recorded, and only one patient stopped therapy due to obstinate constipation. No difference in the clinical efficacy and safety has been recorded between groups treated with different doses of LGG. The present prospective clinical trial demonstrates, for the first time, that LGG in monotherapy is safe and effective for the induction of remission in UC patients with mild–moderate disease activity (ClinicalTrials.gov identifier: NCT04102852). Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

14 pages, 2706 KiB

Open AccessArticle

Microbial Populations in Ruminal Liquid Samples from Young Beefmaster Bulls at Both Extremes of RFI Values

by Nelson Manzanares-Miranda, Jose F. Garcia-Mazcorro, Eduardo B. Pérez-Medina, Anakaren Vaquera-Vázquez, Alejandro Martínez-Ruiz, Yareellys Ramos-Zayas and Jorge R. Kawas

Microorganisms 2023, 11(3), 663; https://doi.org/10.3390/microorganisms11030663 - 06 Mar 2023

Cited by 2 | Viewed by 1133

Abstract

The gut microbiota is involved in the productivity of beef cattle, but the impact of different analysis strategies on microbial composition is unclear. Ruminal samples were obtained from Beefmaster calves (n = 10) at both extremes of residual feed intake (RFI) values [...] Read more.

The gut microbiota is involved in the productivity of beef cattle, but the impact of different analysis strategies on microbial composition is unclear. Ruminal samples were obtained from Beefmaster calves (n = 10) at both extremes of residual feed intake (RFI) values (5 with the lowest and 5 with the highest RFI) from two consecutive days. Samples were processed using two different DNA extraction methods. The V3 and V4 regions of the 16S rRNA gene were amplified using PCR and sequenced with a MiSeq instrument (Illumina). We analyzed 1.6 million 16S sequences from all 40 samples (10 calves, 2 time points, and 2 extraction methods). The abundance of most microbes was significantly different between DNA extraction methods but not between high-efficiency (LRFI) and low-efficiency (HRFI) animals. Exceptions include the genus Succiniclasticum (lower in LRFI, p = 0.0011), and others. Diversity measures and functional predictions were also mostly affected by DNA extraction methods, but some pathways showed significant differences between RFI levels (e.g., methylglyoxal degradation, higher in LRFI, p = 0.006). The results suggest that the abundance of some ruminal microbes is associated with feed efficiency and serves as a cautionary tale for the interpretation of results obtained with a single DNA extraction method. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

15 pages, 3012 KiB

Open AccessArticle

Improved Quantitative Real-Time PCR Protocol for Detection and Quantification of Methanogenic Archaea in Stool Samples

by Agata Anna Cisek, Iwona Bąk and Bożena Cukrowska

Microorganisms 2023, 11(3), 660; https://doi.org/10.3390/microorganisms11030660 - 05 Mar 2023

Cited by 4 | Viewed by 2134

Abstract

Methanogenic archaea are an important component of the human and animal intestinal microbiota, and yet their presence is rarely reported in publications describing the subject. One of the methods of quantifying the prevalence of methanogens is quantitative real-time PCR (qPCR) of the methanogen-specific [...] Read more.

Methanogenic archaea are an important component of the human and animal intestinal microbiota, and yet their presence is rarely reported in publications describing the subject. One of the methods of quantifying the prevalence of methanogens is quantitative real-time PCR (qPCR) of the methanogen-specific mcrA gene, and one of the possible reasons for detection failure is usually a methodology bias. Here, we refined the existing protocol by changing one of the primers and improving the conditions of the qPCR reaction. As a result, at the expense of a slightly lower yet acceptable PCR efficiency, the new assay was characterized by increased specificity and sensitivity and a wider linear detection range of 7 orders of magnitude. The lowest copy number of mcrA quantified at a frequency of 100% was 21 copies per reaction. The other validation parameters tested, such as reproducibility and linearity, also gave satisfactory results. Overall, we were able to minimize the negative impacts of primer dimerization and other cross-reactions on qPCR and increase the number of not only detectable but also quantifiable stool samples—or in this case, chicken droppings. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

13 pages, 1801 KiB

Open AccessArticle

Evaluation of Bacterial Composition and Viability of Equine Feces after Processing for Transplantation

by Clémence Loublier, Bernard Taminiau, Julia Heinen, Laureline Lecoq, Hélène Amory, Georges Daube and Carla Cesarini

Microorganisms 2023, 11(2), 231; https://doi.org/10.3390/microorganisms11020231 - 17 Jan 2023

Cited by 3 | Viewed by 2592

Abstract

Fecal microbiota transplantation (FMT) has been used empirically for decades in equine medicine to treat intestinal dysbiosis but evidence-based information is scarce. This in vitro study aimed at assessing the effect of a commonly used pre-FMT processing method on the bacterial composition and [...] Read more.

Fecal microbiota transplantation (FMT) has been used empirically for decades in equine medicine to treat intestinal dysbiosis but evidence-based information is scarce. This in vitro study aimed at assessing the effect of a commonly used pre-FMT processing method on the bacterial composition and viability of the fecal filtrate. Three samples of fresh equine manure (T₀) were processed identically: the initial manure was mixed with 1 L of lukewarm water and chopped using an immersion blender to obtain a mixture (T₁), which was left uncovered during 30 min (T₂) and percolated through a sieve to obtain a fecal filtrate (T₃). Samples were taken throughout the procedure (Tn) and immediately stored at 4 °C until processing. The 16S rDNA amplicon profiling associated with propidium monoazide treatment was performed on each sample to select live bacteria. Analyses of α and β diversity and main bacterial populations and quantitative (qPCR) analysis were performed and statistically compared (significance p < 0.05) between time points (T₀–T₃). No significant differences in ecological indices or mean estimated total living bacteria were found in the final fecal filtrate (T₃) in regard to the original manure (T₀); however, relative abundances of some minor genera (Fibrobacter, WCHB1-41_ge and Akkermansia) were significantly different in the final filtrate. In conclusion, the results support the viability of the major bacterial populations in equine feces when using the described pre-FMT protocol. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

24 pages, 3646 KiB

Open AccessArticle

Different Impacts of Heat-Killed and Viable Lactiplantibacillus plantarum TWK10 on Exercise Performance, Fatigue, Body Composition, and Gut Microbiota in Humans

by Chia-Chia Lee, Yi-Chu Liao, Mon-Chien Lee, Yi-Chen Cheng, Shiou-Yun Chiou, Jin-Seng Lin, Chi-Chang Huang and Koichi Watanabe

Microorganisms 2022, 10(11), 2181; https://doi.org/10.3390/microorganisms10112181 - 03 Nov 2022

Cited by 8 | Viewed by 2600

Abstract

Lactiplantibacillus plantarum TWK10, a probiotic strain, has been demonstrated to improve exercise performance, regulate body composition, and ameliorate age-related declines. Here, we performed a comparative analysis of viable and heat-killed TWK10 in the regulation of exercise performance, body composition, and gut microbiota in [...] Read more.

Lactiplantibacillus plantarum TWK10, a probiotic strain, has been demonstrated to improve exercise performance, regulate body composition, and ameliorate age-related declines. Here, we performed a comparative analysis of viable and heat-killed TWK10 in the regulation of exercise performance, body composition, and gut microbiota in humans. Healthy adults (n = 53) were randomly divided into three groups: Control, TWK10 (viable TWK10, 3 × 10¹¹ colony forming units/day), and TWK10-hk (heat-killed TWK10, 3 × 10¹¹ cells/day) groups. After six-week administration, both the TWK10 and TWK10-hk groups had significantly improved exercise performance and fatigue-associated features and reduced exercise-induced inflammation, compared with controls. Viable TWK10 significantly promoted improved body composition, by increasing muscle mass proportion and reducing fat mass. Gut microbiota analysis demonstrated significantly increasing trends in the relative abundances of Akkermansiaceae and Prevotellaceae in subjects receiving viable TWK10. Predictive metagenomic profiling revealed that heat-killed TWK10 administration significantly enhanced the signaling pathways involved in amino acid metabolisms, while glutathione metabolism, and ubiquinone and other terpenoid-quinone biosynthesis pathways were enriched by viable TWK10. In conclusion, viable and heat-killed TWK10 had similar effects in improving exercise performance and attenuating exercise-induced inflammatory responses as probiotics and postbiotics, respectively. Viable TWK10 was also highly effective in regulating body composition. The differences in efficacy between viable and heat-killed TWK10 may be due to differential impacts in shaping gut microbiota. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

11 pages, 1723 KiB

Open AccessArticle

The Gut Microbiota at Different Developmental Stages of Apis cerana Reveals Potential Probiotic Bacteria for Improving Honeybee Health

by Pham Thi Lanh, Bui Thi Thuy Duong, Ha Thi Thu, Nguyen Thi Hoa, Mi Sun Yoo, Yun Sang Cho and Dong Van Quyen

Microorganisms 2022, 10(10), 1938; https://doi.org/10.3390/microorganisms10101938 - 29 Sep 2022

Cited by 5 | Viewed by 2127

Abstract

Honeybees play a vital role in the ecological environment and agricultural economy. Increasing evidence shows that the gut microbiome greatly influences the host’s health. Therefore, a thorough understanding of gut bacteria composition can lead to the development of probiotics specific for each development [...] Read more.

Honeybees play a vital role in the ecological environment and agricultural economy. Increasing evidence shows that the gut microbiome greatly influences the host’s health. Therefore, a thorough understanding of gut bacteria composition can lead to the development of probiotics specific for each development stage of honeybees. In this study, the gut microbiota at different developmental stages (larvae, pupae, and adults) of the honeybees Apis cerana in Hanoi, Vietnam, was assessed by sequencing the V3–V4 region in the 16S rRNA gene using the Illumina Miseq platform. The results indicated that the richness and diversity of the gut microbiota varied over the investigated stages of A. cenara. All three bee groups showed relative abundance at both phylum and family levels. In larvae, Firmicutes were the most predominant (81.55%); however, they decreased significantly along with the bee development (33.7% in pupae and 10.3% in adults) in favor of Proteobacteria. In the gut of adult bees, four of five core bacteria were found, including Gilliamella apicola group (34.01%) Bifidobacterium asteroides group (10.3%), Lactobacillus Firm-4 (2%), and Lactobacillus Firm-5 (1%). In contrast, pupae and larvae lacked almost all core bacteria except G. apicola (4.13%) in pupae and Lactobacillus Firm-5 (4.04%) in larvae. This is the first report on the gut microbiota community at different developmental stages of A. cerana in Vietnam and provides potential probiotic species for beekeeping. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

25 pages, 5106 KiB

Open AccessArticle

Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects

by Alessandra De Giani, Anna Sandionigi, Jessica Zampolli, Angela Michelotti, Francesco Tursi, Massimo Labra and Patrizia Di Gennaro

Microorganisms 2022, 10(6), 1256; https://doi.org/10.3390/microorganisms10061256 - 20 Jun 2022

Cited by 11 | Viewed by 3318

Abstract

The gut microbiota is implicated in diverse interactions affecting human health. The present study reports a randomized, double-blind, placebo-controlled clinical study conducted by administering a new synbiotic formulation composed of two Lactobacillus strains (L. plantarum and L. acidophilus) and [...] Read more.

The gut microbiota is implicated in diverse interactions affecting human health. The present study reports a randomized, double-blind, placebo-controlled clinical study conducted by administering a new synbiotic formulation composed of two Lactobacillus strains (L. plantarum and L. acidophilus) and one Bifidobacterium strain (B. animalis subsp. lactis) and two types of fructans (fructo-oligosaccharides with a degree of polymerization of 3–5 and inulin-type fructans with 10 DP). The effects of this synbiotic were evaluated on healthy subjects for 28 days and the maintenance of its efficacy was evaluated at the end of a follow-up period of 28 days. The synbiotic treatment contributes to higher biodiversity of the gut microbiota, increasing the community richness with respect to the group with the prebiotics alone and the placebo group. Its positive effect is also reflected in the variation of microbial community structure favoring the beneficial short-chain fatty acids bacterial producers. The amelioration of the health status of the subjects was also established by the reduction of common infectious disease symptom incidence, the stimulation of the gut immune system showing a noteworthy variation of fecal β-defensin2 and calprotectin levels, and the modulation of the response of the respiratory tract’s immune system by salivary IgA as well as total antioxidant capacity biomarkers. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

20 pages, 3011 KiB

Open AccessArticle

Potential Probiotic Lacticaseibacillus paracasei MJM60396 Prevents Hyperuricemia in a Multiple Way by Absorbing Purine, Suppressing Xanthine Oxidase and Regulating Urate Excretion in Mice

by Youjin Lee, Pia Werlinger, Joo-Won Suh and Jinhua Cheng

Microorganisms 2022, 10(5), 851; https://doi.org/10.3390/microorganisms10050851 - 20 Apr 2022

Cited by 18 | Viewed by 4453

Abstract

Hyperuricemia is a metabolic disorder caused by increased uric acid (UA) synthesis or decreased UA excretion. Changes in eating habits have led to an increase in the consumption of purine-rich foods, which is closely related to hyperuricemia. Therefore, decreased purine absorption, increased UA [...] Read more.

Hyperuricemia is a metabolic disorder caused by increased uric acid (UA) synthesis or decreased UA excretion. Changes in eating habits have led to an increase in the consumption of purine-rich foods, which is closely related to hyperuricemia. Therefore, decreased purine absorption, increased UA excretion, and decreased UA synthesis are the main strategies to ameliorate hyperuricemia. This study aimed to screen the lactic acid bacteria (LAB) with purine degrading ability and examine the serum UA-lowering effect in a hyperuricemia mouse model. As a result, Lacticaseibacillus paracasei MJM60396 was selected from 22 LAB isolated from fermented foods for 100% assimilation of inosine and guanosine. MJM60396 showed probiotic characteristics and safety properties. In the animal study, the serum uric acid was significantly reduced to a normal level after oral administration of MJM60396 for 3 weeks. The amount of xanthine oxidase, which catalyzes the formation of uric acid, decreased by 81%, and the transporters for excretion of urate were upregulated. Histopathological analysis showed that the damaged glomerulus, Bowman’s capsule, and tubules of the kidney caused by hyperuricemia was relieved. In addition, the impaired intestinal barrier was recovered and the expression of tight junction proteins, ZO-1 and occludin, was increased. Analysis of the microbiome showed that the relative abundance of Muribaculaceae and Lachnospiraceae bacteria, which were related to the intestinal barrier integrity, was increased in the MJM60396 group. Therefore, these results demonstrated that L. paracasei MJM60396 can prevent hyperuricemia in multiple ways by absorbing purines, decreasing UA synthesis by suppressing xanthine oxidase, and increasing UA excretion by regulating urate transporters. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

Review

Jump to: Research

14 pages, 690 KiB

Open AccessReview

Microbial Interventions to Improve Neonatal Gut Health

by Ranga Nakandalage, Le Luo Guan and Nilusha Malmuthuge

Microorganisms 2023, 11(5), 1328; https://doi.org/10.3390/microorganisms11051328 - 18 May 2023

Cited by 2 | Viewed by 1615

Abstract

The diverse pioneer microbial community colonizing the mammalian gastrointestinal tract is critical for the developing immune system. Gut microbial communities of neonates can be affected by various internal and external factors, resulting in microbial dysbiosis. Microbial dysbiosis during early life affects gut homeostasis [...] Read more.

The diverse pioneer microbial community colonizing the mammalian gastrointestinal tract is critical for the developing immune system. Gut microbial communities of neonates can be affected by various internal and external factors, resulting in microbial dysbiosis. Microbial dysbiosis during early life affects gut homeostasis by changing metabolic, physiological, and immunological status, which increases susceptibility to neonatal infections and long-term pathologies. Early life is crucial for the establishment of microbiota and the development of the host immune system. Therefore, it provides a window of opportunity to reverse microbial dysbiosis with a positive impact on host health. Recent attempts to use microbial interventions during early life have successfully reversed dysbiotic gut microbial communities in neonates. However, interventions with persistent effects on microbiota and host health are still limited. This review will critically discuss microbial interventions, modulatory mechanisms, their limitations, and gaps in knowledge to understand their roles in improving neonatal gut health. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

15 pages, 4179 KiB

Open AccessReview

Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO

by Michalina Banaszak, Ilona Górna, Dagmara Woźniak, Juliusz Przysławski and Sławomira Drzymała-Czyż

Microorganisms 2023, 11(3), 573; https://doi.org/10.3390/microorganisms11030573 - 24 Feb 2023

Cited by 6 | Viewed by 11219

Abstract

Gut microbiota is the aggregate of all microorganisms in the human digestive system. There are 10¹⁴ CFU/mL of such microorganisms in the human body, including bacteria, viruses, fungi, archaea and protozoa. The Firmicutes and Bacteroidetes bacteria phyla comprise 90% of the human [...] Read more.

Gut microbiota is the aggregate of all microorganisms in the human digestive system. There are 10¹⁴ CFU/mL of such microorganisms in the human body, including bacteria, viruses, fungi, archaea and protozoa. The Firmicutes and Bacteroidetes bacteria phyla comprise 90% of the human gut microbiota. The microbiota support the healthy functioning of the human body by helping with digestion (mainly via short-chain fatty acids and amino acids) and producing short-chain fatty acids. In addition, it exhibits many physiological functions, such as forming the intestinal epithelium, intestinal integrity maintenance, the production of vitamins, and protection against pathogens. An altered composition or the number of microorganisms, known as dysbiosis, disrupts the body’s homeostasis and can lead to the development of inflammatory bowel disease, irritable bowel syndrome, and metabolic diseases such as diabetes, obesity and allergies. Several types of disruptions to the gut microbiota have been identified: SIBO (Small Intestinal Bacterial Overgrowth), LIBO (Large Intestinal Bacterial Overgrowth), SIFO (Small Intestinal Fungal Overgrowth), and IMO (Intestinal Methanogen Overgrowth). General gastrointestinal problems such as abdominal pain, bloating, gas, diarrhoea and constipation are the main symptoms of dysbiosis. They lead to malabsorption, nutrient deficiencies, anaemia and hypoproteinaemia. Increased lipopolysaccharide (LPS) permeability, stimulating the inflammatory response and resulting in chronic inflammation, has been identified as the leading cause of microbial overgrowth in the gut. The subject literature is extensive but of limited quality. Despite the recent interest in the gut microbiome and its disorders, more clinical research is needed to determine the pathophysiology, effective treatments, and prevention of small and large intestinal microbiota overgrowth. This review was designed to provide an overview of the available literature on intestinal microbial dysbiosis (SIBO, LIBO, SIFO and IMO) and to determine whether it represents a real threat to human health. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

9 pages, 944 KiB

Open AccessReview

Probiotics in Functional Dyspepsia

by Georgios Tziatzios, Paraskevas Gkolfakis, Gabriela Leite, Ruchi Mathur, Georgia Damoraki, Evangelos J. Giamarellos-Bourboulis and Konstantinos Triantafyllou

Microorganisms 2023, 11(2), 351; https://doi.org/10.3390/microorganisms11020351 - 31 Jan 2023

Cited by 1 | Viewed by 2969

Abstract

Functional dyspepsia (FD) is a common disorder in everyday clinical practice identified nowadays as a multi-factorial, difficult to treat condition with a significant burden on patients’ quality of life (QoL) and healthcare systems worldwide. Despite its high prevalence in the general population, the [...] Read more.

Functional dyspepsia (FD) is a common disorder in everyday clinical practice identified nowadays as a multi-factorial, difficult to treat condition with a significant burden on patients’ quality of life (QoL) and healthcare systems worldwide. Despite its high prevalence in the general population, the precise etiology of the disorder remains elusive, with its pathophysiological spectrum evolving over time, including variable potential mechanisms, i.e., impaired gastric accommodation, gastric motor disorders, hypersensitivity to gastric distention, disorders of the brain–gut axis, as well as less evident ones, i.e., altered duodenal microbiota composition and genetic susceptibility. In light of these implications, a definitive, universal treatment that could be beneficial for all FD patients is not available yet. Recently, probiotics have been suggested to be an effective therapeutic option that could alleviate gastrointestinal symptoms in patients with Irritable Bowel Syndrome (IBS), potentially due to anti-inflammatory properties or by modulating the complex bidirectional interactions between gastrointestinal microbiota and host crosstalk; however, their impact on the multiple aspects of FD remains ambiguous. In this review, we aim to summarize all currently available evidence for the efficacy of probiotics as a novel therapeutic approach for FD. Full article

(This article belongs to the Special Issue Beneficial Microbes and Gastrointestinal Microbiota)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Beneficial Microbes and Gastrointestinal Microbiota

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (11 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI